Treatment of cancer with an anti-KIR antibody: a patent evaluation of US9879082 and US2018208652

ABSTRACT

Introduction: KIR is an inhibitory receptor expressed by natural killer cells that suppress the immune response against tumor cells. There is a great need to discover and develop new therapies focused on inhibiting the action of KIR and consequently improving the immune response in the various types of cancer. Authors of US9879082 and US2018208652 patents propose a method to eradicate cancer that utilizes anti-KIR antibody.

Areas covered: US9879082 and US2018208652 patents describe an anti-KIR antibody, a pharmaceutical composition that contains it, and their application for cancer treatment, particularly, multiple myeloma and acute myeloid leukemia. Anti-KIR antibody is used to a dosage of 0.0003–3 mg antibody/kg patient weight, and is suspended in an isotonic solution consisting of sodium phosphate, sucrose, NaCl, and polysorbate 80.

Expert opinion: The results of the clinical trials only support trials regarding the pharmacokinetic, pharmacodynamic, safety, and tolerability. In addition, these results demonstrate that treatment with the anti-KIR antibody can induce an antitumor response in cancer patients.

KEYWORDS:

• KIR
• cancer
• immunotherapy
• patent
• antibody

Acknowledgments

The authors thank the Mexican people for the support, through their taxes, provided for the development of this article.

Authors’ contributions

M Perez-Santos designed the study, obtained data of antibodies patent, and drafted the paper; T Guerrero-González and E Gómez-Conde designed the study, analyzed state art of patent, and drafted the paper; Jorge Cebada and A Flores analyzed chemistry conditions of antibodies; N Villa-Ruano analyzed biological conditions of antibodies.

Declaration of interest

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Additional information

Funding

This paper was not funded.